annb0t
Top 20
Bionomics Limited (NASDAQ: BNOX) released a comprehensive analysis of the data from its Phase 2 PREVAIL study to evaluate the efficacy and safety of BNC210 for the acute treatment of Social Anxiety Disorder (SAD). The company said the data support the late-stage development of BNC210 in SAD. While PREVAILÂ did not meet its primary endpoint, the December 2022 topline data readout revealed encouraging trends in the prespecified endpoints that focused on individual phases of the public speaking t...
>>> Read more: Bionomics Reveals Detailed Data From Its Flunked Anxiety Trial, Shows Reductions In Anxiety Across Multiple Phases
>>> Read more: Bionomics Reveals Detailed Data From Its Flunked Anxiety Trial, Shows Reductions In Anxiety Across Multiple Phases
